AES-135

• UNSPSC Description:

  AES-135, a hydroxamic acid-based pan-HDAC inhibitor, prolongs survival in an orthotopic mouse model of pancreatic cancer. AES-135 inhibits HDAC3, HDAC6, HDAC8, and HDAC11 with IC50s ranging from 190-1100 nM[1].

• Target Antigen:

  HDAC

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage;Epigenetics

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/AES-135.html

• Purity:

  98.21

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  CC(C)(C)C1=CC=C(CN(C(CN(CC2=C(F)C(F)=C(F)C(F)=C2F)S(=O)(C3=CC=C(F)C=C3)=O)=O)C4=CC=C(C(NO)=O)C=C4)C=C1

• Molecular Weight:

  693.66

• References & Citations:

  [1]Shouksmith AE, et al. Identification and Characterization of AES-135, a Hydroxamic Acid-Based HDAC Inhibitor That Prolongs Survival in an Orthotopic Mouse Model of Pancreatic Cancer. J Med Chem. 2019 Mar 14;62(5):2651-2665.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  2361659-61-0